Tremfya OverviewGuselkumab is a monoclonal antibody. By targeting the IL-23 subunit alpha (p19 subunit) (which is not part of IL-12) guselkumab was designed to block interleukin-23 but not IL-12. Guselkumab was developed by Janssen Global Services, LLC. In July 2017 it gained US FDA approval for treatment of plaque psoriasis. It is branded as Tremfya. It has undergone phase III clinical trials comparing it with ustekinumab and adalimumab. See also Ustekinumab, a monoclonal antibody ta...
Read more Tremfya Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Guselkumab
Recent Tremfya Forums:Be the first to start a discussion about this drug.
Possible Dosages for this and Related Drugs:
- Injection: 100mg/ml
NDC Database Records for Tremfya: (1 result)Sorted by National Drug Code
- 57894-640 Tremfya 100 mg/ml Subcutaneous Injection by Janssen Biotech, Inc.